Ptc Therapeutics (PTCT) Non-Current Deferred Tax Liability (2018 - 2024)

Ptc Therapeutics' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $55.9 million for Q3 2024.

• In Q3 2024, Non-Current Deferred Tax Liability rose 7.67% year-over-year to $55.9 million; the TTM figure through Sep 2024 stood at $55.9 million (up 7.67% YoY), while the FY2023 annual figure was $55.9 million, down 45.64% from the prior year.
• Non-Current Deferred Tax Liability was $55.9 million for Q3 2024 at Ptc Therapeutics, roughly flat from $55.9 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $137.1 million in Q4 2021 to a low of $51.9 million in Q3 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $105.6 million across 5 years, with a median of $130.9 million in 2020.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability rose 12.39% in 2022, then tumbled 62.13% in 2023.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $136.7 million in 2020, then climbed by 0.27% to $137.1 million in 2021, then slipped by 25.0% to $102.8 million in 2022, then plunged by 45.64% to $55.9 million in 2023, then climbed by 0.01% to $55.9 million in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at $55.9 million (Q3 2024), $55.9 million (Q2 2024), and $55.9 million (Q1 2024), per Business Quant data.